Eli Lilly's 340B Termination Turns Into Litigation and Congressional Pushback — Tampa General Sues in Federal Court, 72 House Members Demand HHS Act
Eli Lilly's June 1 five-day ultimatum escalated on June 18, 2026, when the manufacturer cut off 340B pricing for covered entities that refused to share in-house pharmacy claims data — Lilly directed wholesaler McKesson to end Tampa General Hospital's discounts after it missed the deadline, per the hospital's complaint. Tampa General sued Lilly on July 2 in the U.S. District Court for the Middle District of Florida, alleging the cutoff raised its average costs for Lilly medications 25-50% — losses the complaint pegs at roughly $24.7 million a year, including a 35.9% jump on Mounjaro.
Separately, 72 bipartisan U.S. House members — led by Reps. Doris Matsui (D-CA) and Jack Bergman (R-MI) — signed an early-July letter to HHS Secretary Kennedy and HRSA Administrator Engels urging use of 'any enforcement mechanisms available' against Lilly's move and restoration of 340B pricing.
Coverage so far documents hospitals as the entities cut off; no health-center termination has been confirmed, but FQHCs dispensing Lilly products face the same claims-data condition documented in the June 1 ultimatum item and should confirm their data-sharing posture now.
Key takeaways
- Lilly's threatened termination became real on June 18 — covered entities that didn't share in-house claims data lost 340B pricing; hospitals are the documented cutoff group so far.
- Tampa General's federal suit (M.D. Fla., July 2) puts a number on the damage: 25-50% higher Lilly drug costs, ~$24.7M/year per the complaint.
- 72 bipartisan House members are pressuring HHS/HRSA to intervene — FQHCs dispensing Lilly products should confirm their claims-data enrollment status now.
Source packet
This story's linked evidence + 4 related tracked stories with theirs — one print-ready digest for your team or board packet.
Free — unlocks the packet and submits a single opt-in for Intel Brief. Eligible addresses are subscribed immediately and no confirmation email is sent; a prior unsubscribe, verified deletion, or bounce is not overridden. Individual sources are always clickable above, no email needed.
FQHC Talent. (2026, July 10). Eli Lilly's 340B Termination Turns Into Litigation and Congressional Pushback — Tampa General Sues in Federal Court, 72 House Members Demand HHS Act. Linked evidence: WUSF (Health News Florida); Essential Hospitals; BioPharma Dive. Retrieved September 11, 2026, from https://www.fqhctalent.com/intel/lilly-340b-termination-tampa-general-lawsuit-house-letter-july-2026
More in Risk & Compliance
Aug 27
OCR's 55th HIPAA access action adds a current records-request workflow warning
Aug 21
A vendor that archives the EHR you decommissioned was breached — at least seven health centers are affected, and its own client list is provably incomplete
Aug 21
HHS asks clinicians whether federal vaccine-recommendation categories should change — comments due September 20; nothing changes yet
Aug 13
A final rule takes effect October 13 barring federal Medicaid and CHIP payment for a service line more than a dozen tracked health centers advertise — and the age cutoff is different in Medicaid than in CHIP